Sublocade (Buprenorphine) Patent Expiration, LOE Window & CMS Spending

Sublocade (Buprenorphine) by Indivior: FDA Orange Book LOE 2038-06-22, 12 AB generics, $599.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIndivior
FDA Application & PathwayN209819 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-06-22
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$599.4M
2024 Medicare Part D Spend$50.5M
2024 Medicaid Spend$548.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel